Stock comparison
Aktis Oncology
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AKTS
Aktis Oncology
Market cap
$1.09B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AKTS | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 55D | 79B | HALO |
| Benjamin Graham | 46D | 83A | HALO |
| Philip Fisher | 82C | 65B | AKTS |
| Peter Lynch | 5F | 53D | HALO |
| Joel Greenblatt | 4F | 40D | HALO |
| Charlie Munger | 82D | 80C | AKTS |
| Terry Smith | 88C | 84A | AKTS |
Side-by-side metrics
| Metric | AKTS | HALO |
|---|---|---|
| Market cap | $1.09B | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | - | 10.2x |
| ROIC (TTM) | -10.12% | 23.65% |
| Gross margin | 89.19% | 81.24% |
| Net margin | -7.55% | 23.13% |
| Revenue CAGR 5y | - | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.0x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AKTS leads on
- P/E (TTM)-vs 24.0x+200%
- EV/EBIT-vs 10.2x+191%
- Debt / Equity0.0xvs 1.0x+98%
- Gross margin89.19%vs 81.24%+9%
HALO leads on
- ROIC (TTM)23.65%vs -10.12%+143%
- Net margin23.13%vs -7.55%+103%
- Market cap$8.1Bvs $1.09B+87%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.